
## Martin J Brodie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8033907/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Identification of Refractory Epilepsy. New England Journal of Medicine, 2000, 342, 314-319.	27.0	4,264
2	Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51, 1069-1077.	5.1	3,400
3	Drug-Resistant Epilepsy. New England Journal of Medicine, 2011, 365, 919-926.	27.0	959
4	Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs. JAMA Neurology, 2018, 75, 279.	9.0	910
5	Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Research, 1999, 37, 81-87.	1.6	431
6	Effectiveness of First Antiepileptic Drug. Epilepsia, 2001, 42, 1255-1260.	5.1	372
7	Lamotrigine-Associated Rash: Risk/Benefit Considerations in Adults and Children. Epilepsia, 1999, 40, 985-991.	5.1	310
8	Enzyme induction with antiepileptic drugs: Cause for concern?. Epilepsia, 2013, 54, 11-27.	5.1	293
9	Epilepsy in later life. Lancet Neurology, The, 2009, 8, 1019-1030.	10.2	269
10	Dose-dependent Safety and Efficacy of Zonisamide: A Randomized, Double-blind, Placebo-controlled Study in Patients with Refractory Partial Seizures. Epilepsia, 2005, 46, 31-41.	5.1	238
11	Does the Cause of Localisationâ€Related Epilepsy Influence the Response to Antiepileptic Drug Treatment?. Epilepsia, 2001, 42, 357-362.	5.1	227
12	Staged approach to epilepsy management. Neurology, 2002, 58, S2-8.	1.1	214
13	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?. Epilepsia, 2018, 59, 37-66.	5.1	206
14	Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. Pharmacological Reviews, 2016, 68, 563-602.	16.0	186
15	Epilepsy in elderly people. BMJ: British Medical Journal, 2005, 331, 1317-1322.	2.3	152
16	30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurology, The, 2020, 19, 544-556.	10.2	134
17	Concentration-Effect Studies with Topiramate on Selected Enzymes and Intermediates of the GABA Shunt. Epilepsia, 2000, 41, 30-34.	5.1	127
18	Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology, 2020, 94, 1032-1037.	1.1	116

MARTIN J BRODIE

#	Article	IF	CITATIONS
19	How Common Is Catamenial Epilepsy?. Epilepsia, 1993, 34, 827-831.	5.1	111
20	Circulating Hormones and Pituitary Responsiveness in Young Epileptic Men Receiving Longâ€Term Antiepileptic Medication. Epilepsia, 1988, 29, 468-475.	5.1	108
21	Gabapentin versus Lamotrigine Monotherapy: A Double-blind Comparison in Newly Diagnosed Epilepsy. Epilepsia, 2002, 43, 993-1000.	5.1	104
22	Drug Interactions that Matter. Drugs, 1988, 36, 83-110.	10.9	99
23	Hormone Profiles in Young Adults with Epilepsy Treated with Sodium Valproate or Lamotrigine Monotherapy. Epilepsia, 2001, 42, 1002-1006.	5.1	95
24	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	8.2	90
25	Pharmacokinetics and Drug Interactions with Zonisamide. Epilepsia, 2007, 48, 435-441.	5.1	88
26	Management of epilepsy in women. Lancet Neurology, The, 2019, 18, 481-491.	10.2	86
27	Topiramate in Refractory Epilepsy: A Prospective Observational Study. Epilepsia, 2000, 41, 977-980.	5.1	82
28	Drug Interactions in Epilepsy. Epilepsia, 1992, 33, S13-22.	5.1	80
29	Tiagabine Pharmacology in Profile. Epilepsia, 1995, 36, S7-S9.	5.1	80
30	Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy and Behavior, 2017, 71, 73-78.	1.7	77
31	Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy and Behavior, 2005, 6, 382-387.	1.7	67
32	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia, 2018, 59, 1727-1739.	5.1	67
33	Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy and Behavior, 2006, 8, 434-437.	1.7	57
34	Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons. Epilepsia, 2008, 49, 99-101.	5.1	54
35	Pharmacokinetic Optimisation of Anticonvulsant Therapy. Clinical Pharmacokinetics, 1992, 23, 216-230.	3.5	52
36	The Star Systems. CNS Drugs, 2001, 15, 1-12.	5.9	52

5.9 52

MARTIN J BRODIE

#	Article	IF	CITATIONS
37	Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. British Journal of Pharmacology, 1999, 126, 1634-1638.	5.4	47
38	Intradose and Circadian Variation in Circulating Carbamazepine and Its Epoxide in Epileptic Patients: A Consequence of Autoinduction of Metabolism. Epilepsia, 1987, 28, 286-294.	5.1	44
39	Levetiracetam in refractory epilepsy: a prospective observational study. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 23-27.	2.0	44
40	Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. JAMA Neurology, 2020, 77, 574.	9.0	41
41	Development and Validation of the Glasgow Epilepsy Outcome Scale (GEOS): A New Instrument for Measuring Concerns about Epilepsy in People with Mental Retardation. Epilepsia, 2001, 42, 1043-1051.	5.1	39
42	Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Epilepsy Research, 2016, 119, 62-66.	1.6	39
43	Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561774208.	3.5	39
44	Management Strategies for Refractory Localization-Related Seizures. Epilepsia, 2001, 42, 27-30.	5.1	38
45	Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy and Behavior, 2002, 3, 140-146.	1.7	37
46	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study. Epilepsy and Behavior, 2021, 115, 107658.	1.7	37
47	Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy. Epilepsy and Behavior, 2016, 54, 100-103.	1.7	34
48	Prospective audits with newer antiepileptic drugs in focal epilepsy: Insights into population responses?. Epilepsy and Behavior, 2014, 31, 73-76.	1.7	33
49	Lamotrigine – An Update. Canadian Journal of Neurological Sciences, 1996, 23, S6-S9.	0.5	32
50	Zonisamide clinical trials: European experience. Seizure: the Journal of the British Epilepsy Association, 2004, 13, S66-S70.	2.0	32
51	Cannabinoids for epilepsy: What do we know and where do we go?. Epilepsia, 2018, 59, 291-296.	5.1	32
52	A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy and Behavior, 2010, 17, 455-460.	1.7	31
53	Adjunctive lacosamide—5 Years' clinical experience. Epilepsy Research, 2014, 108, 1385-1391.	1.6	31
54	Outcomes in Elderly Patients With Newly Diagnosed and Treated Epilepsy. International Review of Neurobiology, 2007, 81, 253-263.	2.0	30

4

Martin J Brodie

#	Article	IF	CITATIONS
55	ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia, 2022, 63, 316-334.	5.1	28
56	Monostars: An Aid to Choosing an Antiepileptic Drug as Monotherapy. Epilepsia, 1999, 40, s17-s22.	5.1	27
57	The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia, 2021, 62, 1057-1063.	5.1	27
58	Nifedipine for Epilepsy? A Double-Blind, Placebo-Controlled Trial. Epilepsia, 1992, 33, 346-352.	5.1	26
59	Selection of Antiepileptic Drugs in Adults. Neurologic Clinics, 2009, 27, 967-992.	1.8	25
60	Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites. Epilepsia, 1996, 37, 1100-1106.	5.1	21
61	Tiagabine in the Management of Epilepsy. Epilepsia, 1997, 38, S23.	5.1	21
62	Response to Antiepileptic Drug Therapy: Winners and Losers. Epilepsia, 2005, 46, 31-32.	5.1	19
63	Adenosine monophosphate as a mediator of ATP effects at P1 purinoceptors. British Journal of Pharmacology, 1998, 124, 818-824.	5.4	17
64	Highâ€mobility group box 1 as a predictive biomarker for drugâ€resistant epilepsy: A proofâ€ofâ€concept study. Epilepsia, 2022, 63, e1.	5.1	17
65	Characteristics and treatment outcomes of newly diagnosed epilepsy in older people: A 30â€year longitudinal cohort study. Epilepsia, 2020, 61, 2720-2728.	5.1	14
66	Pharmacological outcomes in teenagers with newly diagnosed epilepsy: A 30â€year cohort study. Epilepsia, 2019, 60, 1083-1090.	5.1	11
67	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COV-E study. Epilepsy and Behavior, 2021, 123, 108261.	1.7	8
68	Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. British Journal of Pharmacology, 1997, 121, 923-926.	5.4	7
69	Lack of Major Effects on Mouse Brain Adenosine A <sub>1</sub> Receptors of Oral Carbamazepine and Calcium Antagonists. Epilepsia, 1991, 32, 729-734.	5.1	6
70	Building New Understandings in Epilepsy: Maximizing Patient Outcomes Without Sacrificing Seizure Control. Epilepsia, 2003, 44, 1-2.	5.1	6
71	Adjunctive brivaracetam – A prospective audit of outcomes from an epilepsy clinic. Epilepsy and Behavior, 2021, 116, 107746.	1.7	5
72	The Teenagers' Service: An Evaluation of Epilepsy Care. Epilepsia, 1997, 38, S5.	5.1	4

MARTIN J BRODIE

#	Article	IF	CITATIONS
73	Markov modelling of treatment response in a 30-year cohort study of newly diagnosed epilepsy. Brain, 2022, 145, 1326-1337.	7.6	3
74	EUCARE—past, present, and future. Lancet Neurology, The, 2003, 2, 269.	10.2	1
75	Building new understandings in epilepsy: maximizing patient outcomes without sacrificing seizure control. Epilepsia, 2003, 44 Suppl 4, 1-2.	5.1	1
76	Role of levetiracetam in the treatment of epilepsy. Epileptic Disorders, 2003, 5 Suppl 1, S65-72.	1.3	1
77	To the Editor. Epilepsy and Behavior, 2001, 2, 616.	1.7	0